These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Henderson MX; Peng C; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356 [TBL] [Abstract][Full Text] [Related]
5. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice. Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein. Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824 [TBL] [Abstract][Full Text] [Related]
7. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo. Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532 [TBL] [Abstract][Full Text] [Related]
8. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688 [TBL] [Abstract][Full Text] [Related]
10. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152 [TBL] [Abstract][Full Text] [Related]
11. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653 [TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
13. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function. Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688 [TBL] [Abstract][Full Text] [Related]
14. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998 [TBL] [Abstract][Full Text] [Related]
15. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors. Pajarillo E; Rizor A; Lee J; Aschner M; Lee E Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588 [TBL] [Abstract][Full Text] [Related]
16. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease. Daher JP Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286 [TBL] [Abstract][Full Text] [Related]